Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS)
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS) (moderate certainty).
1 finding from 1 review
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Second cancer‐ related mortality
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiac disease‐ related mortality
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Complete response rate
The intervention showed no clear difference in complete response rate (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention may leads to higher mortality (calculated instead of overall survival) (low certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS)
The intervention showed no clear difference in relapse, progression or death (calculated instead of PFS) (low certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review
Xerostomia (dry mouth relief) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993: positive response (>25 mm change in VAS score) in 25% of participants on placebo, 51% on pilocarpine 5 mg tds, 47% on pilocarpine 10 mg tds. LeVeque 1993: positive response in 7% on placebo vs 42% on…
2 studies · 278 participants
GRADE not reported
Parasympathomimetic drugs (choline esters, cholinesterase inhibitors) vs No treatment
Outcome not reported · Patients with radiation-induced salivary gland dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Other oral symptoms (oral discomfort, dysphonia) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Both studies assessed oral discomfort and dysphonia (Johnson 1993; LeVeque 1993); pilocarpine reported to improve associated symptoms of salivary gland dysfunction (oral discomfort, dysphonia). No pooled data.
2 studies · 278 participants
GRADE not reported
Salivary flow rate · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Intervention not reported
year overall survival in patients of good performance status (WHO performance status 0‐1) · adults with non small cell lung cancer who are not felt to be curable
1 finding from 1 review
Intervention not reported
year overall survival in patients of poor performance status (WHO performance status 2‐4) · adults with non small cell lung cancer who are not felt to be curable
The intervention showed no clear difference in year overall survival in patients of poor performance status (WHO… (moderate certainty).
1 finding from 1 review